Leading source of Financial News, Investor Forums, CEO Interviews, Financial Columnists, Stock Information

Pharma & Biotech

Add to MyProactive

Admedus Ltd - Admedus sells distribution rights to CardioCel® and VascuCel® product range for $36.2 million

Admedus makes "transformational" sale of CardioCel® and VascuCel® for $36.2 million

1 day, 14 hours ago

Cellmid Limited - Cellmid's share placement raises $1.5 million to fund évolis® anti-aging hair product growth

Cellmid secures new TV shopping agreement for évolis® anti-ageing hair products

1 day, 17 hours ago

Cellmid Limited - Cellmid goes into trading halt ahead of proposed capital raising

Cellmid goes into trading halt ahead of proposed capital raising

5 days, 20 hours ago

Cellmid Limited - Cellmid signs new distribution agreement for évolis®; opens in Europe with leading retailer

Cellmid signs new supply and distribution agreements for évolis® hair products

2 weeks, 1 day ago

Imugene Ltd - Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studies

Imugene presents HER2 immuno-oncology vaccines success at ESMO ahead of 2020 studies

2 weeks, 1 day ago

Kazia Therapeutics Ltd - Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

2 weeks, 1 day ago

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals journal publication confirms discovery

Paradigm Biopharmaceuticals journal publication confirms discovery, shares surge

2 weeks, 2 days ago

Kazia Therapeutics Ltd - Kazia Therapeutics presents ovarian cancer study at conference

Kazia Therapeutics presents ovarian cancer study at conference

2 weeks, 2 days ago

Cellmid Limited - Cellmid secures R&D tax incentive for midkine and FGF5 inhibitor programs

Cellmid secures R&D tax incentive for midkine and FGF5 inhibitor programs

2 weeks, 5 days ago

Kazia Therapeutics Ltd - Kazia Therapeutics shares pipeline results with market and clinicians

Kazia Therapeutics to share pipeline results with market and clinicians

2 weeks, 6 days ago

THC Global Group Ltd - THC Global aims to launch medicinal cannabis for Australian patients by early 2020

THC Global aims to launch medicinal cannabis for Australian patients by early 2020

3 weeks ago

MMJ Group Holdings Ltd - MMJ Group Holdings investment BevCanna enters supply agreement to produce high-purity cannabinoid-rich distillate

Retail & consumer

MMJ Group Holdings investment BevCanna enters supply agreement to produce high-purity cannabinoid-rich distillate

3 weeks, 5 days ago

Kazia Therapeutics Ltd - Kazia Therapeutics Ltd to present at the 14th annual Neuro Oncology meeting in France

Kazia Therapeutics to present on phase II study of GDC-0084 in glioblastoma at Neuro Oncology meeting in France

3 weeks, 5 days ago

MMJ Group Holdings Ltd - MMJ Group investment BevCanna signs joint cultivation agreement led by farm start-up expert Joey Bedard-Brunet

MMJ Group investment BevCanna signs joint cultivation agreement led by farm start-up expert Joey Bedard-Brunet

3 weeks, 6 days ago

Kazia Therapeutics Ltd - Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award

Kazia Therapeutics wins ANZLF Trans-Tasman Innovation and Growth award

on 13/9/19

Kazia Therapeutics Ltd - Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug

Kazia Therapeutics confirms successful completion of phase I study of its childhood cancer drug

on 12/9/19

Pharmaxis Ltd - Pharmaxis features in APAC’s top 100 most innovative pharma companies report

Industry & services

Pharmaxis features in APAC’s top 100 most innovative pharma companies report

on 12/9/19

Paradigm Biopharmaceuticals Ltd - Paradigm Biopharmaceuticals gets FDA clearance for investigational new drug application

Paradigm Biopharmaceuticals gets FDA clearance for investigational new drug application

on 10/9/19

Kazia Therapeutics Ltd - Kazia Therapeutics' cancer drug trials push up valuation to $137 million or $2.20 a share according to Edison research

Kazia Therapeutics' cancer drug trials lift valuation to $137 million or $2.20 a share, according to Edison

on 9/9/19

Kazia Therapeutics Ltd - Kazia Therapeutics a top-10 finalist in the ANZLF Trans-Tasman Innovation and Growth Awards

Kazia Therapeutics a top-10 finalist in ANZLF Trans-Tasman Innovation and Growth Awards

on 6/9/19